Beta-Elemene Blocks Epithelial-Mesenchymal Transition in Human Breast Cancer Cell Line MCF-7 through Smad3-Mediated Down-Regulation of Nuclear Transcription Factors

Xian Zhang1,2, Yinghua Li1, Yang Zhang1*, Jincheng Song3, Qimin Wang4, Luping Zheng2, Dan Liu3

1 Department of Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian, China, 2 Research Institute of Integrated Traditional and Western Medicine of Dalian Medical University, Dalian, China, 3 Graduate Institute of Dalian Medical University, Dalian, China, 4 Department of Pathology, the Second Affiliated Hospital of Dalian Medical University, Dalian, China

Abstract

Epithelial-mesenchymal transition (EMT) is the first step required for breast cancer to initiate metastasis. However, the potential of drugs to block and reverse the EMT process are not well explored. In the present study, we investigated the inhibitory effect of beta-elemene (ELE), an active component of a natural plant-derived anti-neoplastic agent in an established EMT model mediated by transforming growth factor-beta1 (TGF-β1). We found that ELE (40 μg/ml) blocked the TGF-β1-induced phenotypic transition in the human breast cancer cell line MCF-7. ELE was able to inhibit TGF-β1-mediated upregulation of mRNA and protein expression of nuclear transcription factors (SNAI1, SNAI2, TWIST and SIP1), potentially through decreasing the expression and phosphorylation of Smad3, a central protein mediating the TGF-β1 signalling pathway. These findings suggest a potential therapeutic benefit of ELE in treating basal-like breast cancer.

Citation: Zhang X, Li Y, Zhang Y, Song J, Wang Q, et al. (2013) Beta-Elemene Blocks Epithelial-Mesenchymal Transition in Human Breast Cancer Cell Line MCF-7 through Smad3-Mediated Down-Regulation of Nuclear Transcription Factors. PLoS ONE 8(3): e58719. doi:10.1371/journal.pone.0058719

Editor: Neil A. Hotchin, University of Birmingham, United Kingdom

Received November 7, 2012; Accepted February 5, 2013; Published March 14, 2013

Copyright: © 2013 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: dlzlzx001@yahoo.com.cn

Introduction

Breast cancer is the most commonly diagnosed cancer, and the second leading cause of cancer-related deaths in US women [1]. Metastasis is often a lethal component of breast cancer, while other patients die from long-term recurrence [2]. Several steps are involved in cancer metastasis, including epithelial-mesenchymal transition (EMT), invasion, intravasation, adhesion, extravasation and mesenchymal-epithelial transition (MET) [3,4]. Recently, there has been growing interest in investigating the role of EMT in cancer metastasis, as it is the first step in the migration of breast cancer cells [5,6,7,8]. Recent evidence indicates that EMT is associated with cancer cell stemness, chemoresistance and circulating tumor cells in breast cancer [9,10,11,12]. Thus, inhibition of EMT may provide therapeutic potential for improving the prognosis of breast cancer patients.

EMT, essential for physiological processes, is triggered by many stimuli including tumor-stromal cell interactions, hypoxia and growth factors, including transforming growth factor-β (TGF-β) [8,13,14,15]. EMT is defined by the loss of epithelial characteristics accompanied by a mesenchymal phenotype. This phenotype is characterized by reduced expression of epithelial markers (E-cadherin and β-catenin) and elevated expression of mesenchymal markers (N-cadherin, fibronectin and vimentin) [6,16]. These proteins are mainly regulated by transcription repressors, including Snail/SNAI1, Slug/SNAI2, TWIST and SIP1, a master regulator of EMT [17,18,19]. TGF-β, Wnt-, Notch-, Hedgehog-, and NF-kB- dependent pathways can induce and maintain EMT [20], and are often considered targets to block EMT [21]. Interestingly, some natural products, including fucoidan, benzyl isothiocyanate, curcumin, 2-hydroxycinnamaldehyde can block EMT by regulating miRNA [22,23,24,25].

Elemene (1-methyl-1-vinyl-2, 4-diisopropenyl-cyclohexane), an active component of the herbal medicine Curcuma wenyujin, is a novel anti-cancer drug [26]. An extract of elemene contains a mixture of α-, β- and δ-elemene, in which the main component β-elemene (ELE) accounts for 60~72% of total drug [27]. ELE has been clinically used to treat leukaemia and carcinomas in brain, breast, liver and other tissues [26,28,29,30], as one of its formulations has been approved by the State Food and Drug Administration of China for treating primary and secondary brain tumors. In addition, ELE induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells [31], induces apoptosis in bladder cancer T24 cells via downregulation of survivin, Bcl-xl and Mta-1 expression [32], and regulates the activities of Ras/Raf/MEK/ERK and the Akt cascades [33,34]. Collectively, these studies indicate that ELE has apoptosis-inducing activity and regulates signalling pathways critical for cell survival in in vitro systems. However, it is unclear whether ELE plays a role in EMT in human breast cancer cells.

Using an EMT model of the breast cancer cell line MCF-7 treated with TGF-β1, we examined the effect of ELE on EMT-related phenotypic and gene expression changes.
Materials and Methods

Chemicals and Reagents

ELE (98% purity) was purchased from Dalian Jingang Pharmaceuticals, Ltd (Liaoning, China). The main component in the ELE is β-elemene, with a molecular formula of C15H26 and molecular weight of 204.35. There are only small fractions of γ-elemene and δ-elemene, whose molecular formulas are C16H28 and C17H30 and molecular weights are 218.39/204.35, respectively. The biologically available concentration of β-elemene is unclear.

Primary antibodies against E-cadherin, N-cadherin, vimentin, β-catenin, SNAI1/2, TWIST, SIP1, Smad3, p-Smad3 and β-actin were purchased from Abcam Biotechnology (Cambridge, UK). The secondary horseradish peroxidase (HRP)-conjugated goat anti-rabbit-IgG and HRP-conjugated goat anti-mouse-IgG antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Cell Line and Drug Treatment

The human breast cancer cell line MCF-7 was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM/high glucose, 20% fetal bovine serum (FBS), with 1% penicillin/streptomycin (Gibco, Carlsbad, CA, USA). MCF-7 was cultured at 37°C in a humidified incubator (Heraeus, Germany) supplemented with 5% CO2 and seeded at 2.5 × 10^5 cells/ml in 6-well plates (Corning, NY, USA). Cells were maintained in serum-free DMEM/high glucose for 24 hrs, followed by treatment with 10 ng/ml TGF-β1 (R&D Systems, Minneapolis, MN, USA) [35]. Cells were examined in four groups: treated with TGF-β1 and ELE (+TGF-β1/+ELE); TGF-β1 alone (+TGF-β1/-ELE); ELE alone (-TGF-β1/+ELE); or no treatment (-TGF-β1/-ELE).

Western Immunoblot Analysis

MCF-7 cells were washed with ice-cold PBS in duplicate and solubilised in 1% Triton lysis buffer [1% Triton X-100, 50 mmol/L Tris-Cl (pH 7.4), 150 mmol/L NaCl, 10 mmol/L EDTA, 100 mmol/L NaF, 1 mmol/L Na3VO4 (Sigma-Aldrich, Saint Louis, MO, USA), 1 mmol/L PMSF and 2 μg/mL aprotinin] on ice, followed by quantification using the Lowry method. Cell lysates (50 μg) were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to PVDF membranes (Immobilin-P; EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% bovine serum albumin (Sigma-Aldrich, Saint Louis, MO, USA) at RT for 1 hr and incubated overnight at 4°C with the primary antibodies: E-cadherin (1:1000), β-catenin (1:5000), N-cadherin (1:1000), vimentin (1:5000), SNAI1 (1:500), SNAI2 (1:1000), TWIST (1:50), SIP1 (1:100), Smad3 (1:1000), p-Smad3 (1:1000) and β-actin (1:200). The membranes were incubated with the appropriate HRP-conjugated secondary antibodies for 30 mins at RT following incubation with Tris Buffered Saline with Tween-20 (TBST) buffer. The signals were visualized with enhanced chemiluminescence reagent (Beyotime Biotechnology, Nantong, China). Images were analysed using the NIH Image J software.

Real-time PCR (RT-PCR)

Total RNA was extracted through homogenization in 1 mL TRIzol reagent (Invitrogen, Carlsbad, CA, USA), followed by chloroform extraction and isopropanol precipitation. Real-time PCR was performed in a 20 μL mixture containing 1.6 μL of cDNA template, 1 μL of each primer (10 mM), and 10 μL of a SYBR Green master mix (Takara, Dalian, China). Primers used included: 5’-TCAGACAGGAGAGTGAGGAGGAG-3’ (sense) and 5’-GCTTGTGGAGCAGGACATTCT-3’ (antisense) for SNAI1; 5’-CTTCGTGTTGCAAGGAAGCA-3’ (sense) and 5’-GGGAAAATTCATGTTGTTGTTG-3’ (antisense) for SNAI2; 5’-TCTGCGTCTGGAGGATGGAAG-3’ (sense) and 5’-GTATTCCCAGCTTGAGTCT-3’ (antisense) for TWIST; 5’-AGCGCATACGCGCATGGAC-3’ (sense) and 5’-TTCCCTCCTGTGGAGGTGGCTT-3’ (antisense) for SIP1; 5’-ACGAGGCTTGTGGACTGTC-3’ (sense) and 5’-GCAGACTGCTGCTGACAACTC-3’ (sense) and 5’-TGGTGAAGAGCCAGTGGA-3’ (antisense) for human GAPDH. The average expression levels of genes were normalized to the housekeeping gene GAPDH.

Wound Healing Assay

MCF-7 cells were seeded in 10% FBS medium on 6-well plates at a density of 2 × 10^5 cells/well. Cells were either incubated with TGF-β1 or PBS for 24 hrs as positive and negative controls, respectively. Then, cells reaching sub-confluence were scraped and allowed to migrate in serum-free medium for 12 hrs. For ELE-mediated effects, cells were incubated simultaneously with 10 ng/ml TGF-β1 and 40 μg/ml ELE for 24 hrs and subsequently scraped. The cell migration images were photographed at 0, 6, and 12 hrs following scraping. Three to four different locations were visualized and photographed under a Nikon Eclipse TE2000-U phase-contrast inverted microscope (Nikon, Japan). Three replicates of two independent experiments were averaged.

Transwell Migration and Invasion Assay

Cell invasion was measured using a transwell chamber coated with 1–2 mg/ml Matrigel (reconstituted basement membrane; BD Biosciences, Mississauga, Canada). MCF-7 cells (2 × 10^5 per transwell) were added, followed by incubation with 10 ng/ml TGF-β1, in combination with ELE (20, 40, 80 μg/ml) or PBS, at 37°C in an incubator supplemented with 5% CO2. Cells in the upper chamber were removed with a cotton swab after 24 hrs. The remaining cells on the membrane were fixed using methanol for 10 mins, followed by staining with 1% crystal violet solution and washed with PBS. The number of invaded cells was counted per field of view at 200× magnification.

Cell Viability Assay

Cell viability was measured using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded at 5 × 10^4 cells/well in 96-well plates, incubated overnight and then exposed to the indicated concentrations of ELE for the indicated time periods. Thereafter, 20 μL of MTT (Sigma-Aldrich, Saint Louis, MO, USA) solution (5 mg/mL) was added to each well, and cells were incubated for another 4 hrs at 37°C. Following removal of the culture medium, cells were lysed in 200 μL of dimethylsulfoxide (DMSO), and optical density (OD) was measured at 570 nm in a microplate reader (Model 550; Bio-Rad Laboratories, Hercules, CA, USA). The following formula was used: cell viability = (OD of the experimental sample/OD of the control group) × 100%.

Statistical Analyses

The experiments were repeated at least in triplicate. Data are expressed as the mean ± SD. Differences in the results for two groups were evaluated using a Student’s t-test. P < 0.05 was considered to be statistically significant.
Results

TGF-β1 Induces Phenotypic Transition of MCF-7 Cells

We initially attempted to establish an EMT model using a cobblestone-like epithelial breast cancer cell line (MCF-7 treated with 10 ng/ml TGF-β1 for 24 hrs). Consistent with previous studies, TGF-β1-treated MCF-7 cells reduced cell-cell interactions and became fibroblast-like, an EMT-like phenotypic change (Fig. 1A). Western immunoblot analysis showed a marked decrease in E-cadherin and β-catenin expression, and an increase in expression of N-cadherin and vimentin, a characteristic of EMT (Fig. 1B). These data confirmed that TGF-β1 treatment results in EMT in MCF-7 cells.

TGF-β1 Facilitates Migration and Invasion of MCF-7 Cells

As mesenchymal cells move faster than epithelial cells, we next examined the migration and invasion abilities of TGF-β1-treated MCF-7 cells in vitro. In a wound healing assay, MCF-7 cells treated with TGF-β1 for 24 hrs migrated faster than parental MCF-7 cells (P<0.01) and closed the gap 12 hrs after generation (Fig. 2A). Using a transwell assay, TGF-β1 treatment led to more MCF-7 cells migrating and invading the membrane matrix than negative controls (P<0.001 and P = 0.002, respectively) (Fig. 2B).

ELE Blocks TGF-β1-induced EMT in MCF-7 Cells

We next assessed the effect of ELE on TGF-β1-mediated changes of cell morphology and gene expression in MCF-7 cells. Since the MTT assay showed that the IC50 of ELE was 534 μg/ml in TGF-β1-treated MCF-7 cells and 275 μg/ml in parental MCF-7 cells (Figure S1), MCF-7 cells were treated with 10 ng/ml TGF-β1 and 40 μg/ml ELE for 24 hrs. Surprisingly, an epithelial morphology of MCF-7 cells was maintained even in the presence of TGF-β1 (Fig. 3A). Consistent with the morphological observation, expression levels of epithelial E-cadherin and β-catenin and mesenchymal N-cadherin and vimentin were comparable between TGF-β1-treated cells and controls (Fig. 3B). These data indicate that ELE inhibits TGF-β1-induced EMT.

ELE Inhibits TGF-β1-induced Migration and Invasion of MCF-7 Cells

MCF-7 cells treated TGF-β1 and ELE did not close the wound after 12 hrs, similar to MCF-7 cells with ELE alone (P = 0.68, Fig. 4A). The blockage effect of ELE on TGF-β1-dependent migratory ability was confirmed in the transwell assays where the numbers of MCF-7 cells treated with ELE and TGF-β1 migrating and invading the matrix were comparable to cells with ELE alone (P = 0.06 and 0.28, respectively, Fig. 4B).

ELE Represses TGF-β1-mediated Upregulation of Transcriptional Factors that Modulate EMT

RT-PCR analyses showed that TGF-β1 treatment resulted in upregulation of SNAI1, SNAI2, TWIST and SIP1 mRNA expression in MCF-7 cells (Fig. 5A and Figure S2A). Consistent with the TGF-β1-dependent increase in mRNA expression of nuclear transcriptional factors, protein expression levels of these molecules were also elevated in response to TGF-β1 treatment. However, the increased expression of proteins was blocked using 40 μg/ml ELE (Fig. 5B).

ELE Modulates TGF-β1-dependent Smad3 Expression and Phosphorylation

RT-PCR analyses showed that mRNA expression of Smad3 was inhibited using TGF-β1 in MCF-7 (P<0.01, Fig. 6A and Figure S2B). While 20 or 40 μg/ml ELE did not block TGF-β1-mediated downregulation of Smad3 expression, 80 μg/ml ELE significantly enhanced this reduction (P<0.001, Fig. 6A). As Smad3 is a downstream molecule in the TGF-β1 signalling pathway, the phosphorylation levels of Smad3 were significantly increased in response to TGF-β1 treatment (P<0.01, Fig. 6B), although total Smad3 protein levels were slightly decreased, consistent with the mRNA expression. Finally, we found that ELE significantly inhibited phosphorylated Smad3 levels, and further reduced total Smad3 levels, at a concentration of 30 μg/ml (P<0.001, Fig. 6C).

Discussion

TGF-β is a strong activator of EMT and involved in cancer progression and metastasis [36,37,38]. TGF-β is recognized as a master regulator of EMT in this phenotypic transition process [36]. The binding of TGF-β to its receptors leads to activation of a canonical Smad2/3-dependent pathway and subsequently phosphorylated Smad2/3 translocates to the nucleus where cell type-specific expression of TGF-β-responsive genes is regulated,
Figure 2. MCF-7 cells acquire migration and invasion abilities in response to TGF-β1 treatment. (A) Representative pictures of the scratch wound assay. TGF-β1-treated MCF-7 cells migrated faster than controls. The black lines indicated size of the remaining wound. Data from three independent experiments were analyzed and presented as mean ± SD. (P<0.001). (B) Representative pictures in a transwell migration assay (top). The penetrated cells numbers of MCF-7 treated with TGF-β1 for 12 hrs were significantly increased as compared to controls without TGF-β1 (P<0.001). Representative pictures in a transwell invasion assay (bottom). TGF-β1 treatment led to more MCF-7 cells penetrating matrix than controls. (P = 0.002). The results in both transwell migration and invasion assays were obtained from three independent experiments.
doi:10.1371/journal.pone.0058719.g002

Figure 3. ELE blocks TGF-β1-induced EMT in MCF-7 cells. (A) Representative pictures of MCF-7 cells treated with ELE showed that epithelial morphology of cells was maintained even in the presence of TGF-β1. Magnification, 200×. (B) Western immunoblot analysis showed that expression levels of E-cadherin and β-catenin (epithelial markers) and N-cadherin and vimentin (mesenchymal markers) did not differ in cells treated with TGF-β1 and ELE compared to cells with ELE only.
doi:10.1371/journal.pone.0058719.g003
including SNAI1, SNAI2 and SIP1 [39,40]. In addition, there are non-canonical signalling pathways, including the MAP kinases ERK1/2, p38 MAPK, and JNK, the growth and survival kinases PI3K, AKT/PKB, and mTOR, and the small GTP-binding proteins Ras and RhoA [40,41,42].

In the TGF-β signalling pathway, there are several molecular targets with a potential for therapeutic interventions. One of the approaches is inhibition of TGF-β receptor I (TGFβRI) or TGF-β receptor II (TGFβRII) kinase activity, leading to a blockade of the phosphorylation of downstream effectors. However, there are a few clinical trials without success [43,44]. In addition, a number of transcription factors that induce EMT through transcriptional repression of E-cadherin are also potential targets. While there is crosstalk among Snail family members and other transcription factors, including TWIST [45], ZEB1 [46] and SIP1 [47], knocking down Snail gene expression using RNA interference technology can effectively block cancer metastasis [48].

Since ELE was previously shown to regulate the expression and phosphorylation of kinase molecules, we hypothesized that ELE might affect EMT in breast cancer cells by modulating signalling proteins. To test this hypothesis, we initially established an EMT model using an epithelial breast cancer cell line, MCF-7, and examined the effect of ELE on the TGF-β1-dependent signalling pathway and the nuclear transcription factors SNAI1, SNAI2, TWIST and SIP1.

In agreement with previous studies that TGF-β1 induces morphological changes in epithelial cells, we found that MCF-7 treated with TGF-β1 became fibroblast-like similar to EMT, characterized by the expression of the epithelial markers (E-cadherin and β-catenin) and the mesenchymal markers (N-cadherin and vimentin). In addition, this mesenchymal phenotype was associated with more migration and invasiveness capabilities. Surprisingly, ELE blocked the phenotypic changes and abilities of migration and invasion of TGF-β1-treated MCF-7 cells. This blockade may be partially mediated by ELE-dependent regulation...
Figure 5. TGF-β1-mediated upregulation of nuclear transcriptional factors expression was blocked by ELE. (A) RT-PCR analyses showed that mRNA expression levels of transcriptional factors (SNAI1, SNAI2, TWIST and SIP1) were significantly increased in TGF-β1 treated MCF-7 cells (*: \( P < 0.01 \), **: \( P < 0.001 \)). (B) Western immunoblot analysis showed that protein expression levels of SNAI1, SNAI2, TWIST and SIP1 were repressed by ELE treatment, especially in SNAI1 and SNAI2.

Figure 6. ELE facilitates TGF-β1-mediated downregulation of Smad3 expression but inhibits increased Smad3 phosphorylation. (A) RT-PCR analyses showed that TGF-β1 treatment led to downregulation of Smad3 mRNA expression, and ELE enhanced the reduction in Smad3 expression (*: \( P < 0.01 \), **: \( P < 0.001 \)). (B) Western immunoblot analysis showed that the ratio of p-Smad3/total Smad3 was increased in a time-dependent manner with 10 ng/ml TGF-β1 (*: \( P < 0.01 \)), although expression levels of total Smad3 were slightly decreased. (C) TGF-β1-induced Smad3 phosphorylation was blocked by ELE and total Smad3 was further decreased in MCF-7 cells treated with TGF-β1 and ELE (*: \( P < 0.01 \), **: \( P < 0.001 \)).

doi:10.1371/journal.pone.0058719.g005
doi:10.1371/journal.pone.0058719.g006
of nuclear transcription factor expression and TGF-β1-induced Smad3 expression and phosphorylation.

The results of the invasion assay showed a slight increase in MCF-7 cells invading the Matrigel matrix when treated with ELE compared to Figures 2B to 4B. We have previously reported that ELE treatment led to upregulated expression of the oestrogen receptor alpha (ERα) though repressing activity of the Ras/MAPK/ERK pathway in breast cells [49]. As ERα is implicated in tumor invasion through the regulation of miRNA families, it is possible that upregulation of ERα expression may facilitate expression of its target miRNAs that are involved in cell invasion [50]. Since estrogen opposes TGF-β1 effects in MCF-7 cells, it is likely that ELE-induced expression of ERα may antagonize the TGF-β1-mediated EMT [51]. However, a more detailed mechanism by which ELE alone causes a small fraction of cells to invade requires further investigation.

Finally, our data provide a potential mechanism whereby ELE blocks TGF-β1-induced EMT in breast cancer cells in vitro. ELE-dependent inhibition of TGF-β1 effect is mediated by a reduction in Smad3 phosphorylation, enhanced downregulation of Smad3 expression and repressing expression of nuclear transcription factors.

References

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.
2. De Santis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61: 409–418.
3. Meyer T, Hart IR (1998) Mechanisms of tumour metastasis. Eur J Cancer 34: 214–221.
4. Thierry JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871–890.
5. Trimbold AJ, Fukino K, de Brouin A, Wei G, Shen L, et al. (2008) Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68: 937–945.
6. Foroni C, Brogini M, Generali D, Dania G (2012) Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treat Rev 38: 689–697.
7. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, et al. (2009) Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15: 2657–2665.
8. Chen J, Imanaka N, Griffith JD (2010) Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer 102: 351–360.
9. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704–715.
10. Giordano G, Gao H, Auffosi S, Cohen E, Mego M, et al. (2012) Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Mol Cancer Ther.
11. Dave B, Mittal V, Tan NM, Chang JC (2012) Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14: 202.
12. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kümmlig R, Fehm T (2012) Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 14: R15.
13. Tien CF, Kullari R (2007) Mechanisms of metastatic epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101: 816–829.
14. Zavadil J, Bottunger EP (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5769–5774.
15. Massague J (2008) TGFbeta in Cancer. Cell 134: 215–230.
16. Drasin DJ, Robin TP, Ford HL (2011) Breast cancer epithelial-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res 13: 226.
17. de Herreros AG, Peiro S, Nassour M, Savagner P (2010) Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia 15: 135–147.
18. Dihasarathy A, Phadke D, Mav D, Shah RR, Wade PA (2011) The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PLoS One 6: e26514.
19. Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277–279.

Supporting Information

Figure S1 ELE MTT assay. MCF-7 cells were treated with the indicated concentrations of ELE with or without 10 ng/ml TGF-β1. The IC50 for ELE was 534 μg/ml in TGF-β1-treated MCF-7 cells and 275 μg/ml in control cells, respectively. (TIF)

Figure S2 RT-PCR analyses of mRNA expression levels of nuclear transcriptional factors and Smad3. RT-PCR analyses of mRNA expression levels of nuclear transcriptional factors (A) and Smad3 (B) in MCF-7 cells treated with or without 10 ng/ml TGF-β1 in the indicated concentrations of ELE. (TIF)

Author Contributions

Designed the concept of the study; XZ YZ. Carried out cells culture and EMT induction; YL JS. Carried out the molecular studies, participated in the mechanism of β-elemene blockage EMT; XZ DL LZ. Participated in the sequence alignment; QW YL. Performed data gathering and management; JS XZ. Wrote the paper; XZ DL YZ.
37. Roberts AB, Tian F, Byfield SD, Snedden C, Ooshima A, et al. (2006) Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 17: 19–27.
38. Tarasewicz E, Jeruss JS (2012) Phospho-specific Smad3 signaling: Impact on breast oncogenesis. Cell Cycle 11: 2443–2451.
39. Coradini D, Fornili M, Ambrogi F, Boracchi P, Biganzoli E (2012) TGF53 mutation, epithelial-mesenchymal transition, and stenile features in breast cancer subtypes. J Biomed Biotechnol 2012: 254085.
40. Gal A, Sjoblom T, Fedorova L, Imreh S, Brug H, et al. (2008) Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 27: 1210–1250.
41. Parvani JG, Taylor MA, Schiemann WP (2011) Noncanonical TGF-beta signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 16: 127–146.
42. Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156–172.
43. Fransvea E, Angelotti U, Antonaci S, Giannelli G (2008) Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47: 1557–1566.
44. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Felch G, et al. (2010) TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 18: 655–668.
45. Tran DD, Corsa CA, Biocas H, Aft RL, Longmuore GD (2011) Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res 9: 1644–1657.
46. Mellici D, Hay ED, Goodenough DA (2006) Cooperation between snail and LEF-1 transcription factors is essential for TGFbetal-induced epithelial-mesenchymal transition. Mol Biol Cell 17: 1871–1879.
47. Castro Alves C, Rosivatz E, Schott C, Hollweck R, Becker I, et al. (2007) Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol 211: 507–515.
48. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15: 195–206.
49. Zhang B, Zhang X, Tang B, Zheng P, Zhang Y (2012) Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor alpha (E Raf alpha) re-expression. Breast Cancer Res Treat 136: 399–406.
50. Guttila IK, Adams BD, White BA (2012) E Raf alpha, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol Metab 23: 73–82.
51. Ito I, Hanyu A, Wayama M, Goto N, Katsumo Y, et al. (2010) Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation. J Biol Chem 285: 14747–14755.